Screening for Optimal Lung Health
Accurate and early detection is pivotal for many lung diseases.
FLHC: Leveraging the Most Advanced Screening Technology
Here's how we put state-of-the-art solutions to work for Floridians
LDCT—Low-dose CT scanning (LDCT) is a quick and painless screening tool that uses low doses of radiation, comparable to a mammogram, to make detailed images of your lungs. These images are used to detect lung disease at its earliest stages. People who undergo LDCT screenings have a 20% reduced risk of mortality compared with individuals who receive chest x-rays alone.
Artificial Intelligence - FLHC optimizes its LDCT scans with Artificial Intelligence (AI) technology from DeepHealth. DeepHealth AI automates the detection and quantification of lung nodules on chest CT scans, enabling the radiologist to go further than naked-eye assessments. The technology assists with the counting, segmenting, measuring, and volumetry of subtle and suspicious nodules. It helps clinicians reduce time-to-diagnosis and time-to-treatment—which can translate to better outcomes.
Liquid Biopsy - Samples of blood, urine, or other bodily fluid indicate the presence or nature of circulating tumor DNA (ctDNA) from cancer cells. This advanced, non-invasive technique is used in conjunction with imaging to find bio-markers, predict malignancy, and assess treatment response. Liquid biopsy can also aid early diagnosis and refine treatment planning. It is another powerful innovation in our quest for early and accurate detection.
The Facts on
Lung cancer is the leading cause of cancer death worldwide.
About 14.5 million Americans are at high risk for lung cancer, yet only 5.7% get screened. In Florida, only 3% of eligible people are screened.
Symptoms often do not present until lung cancer is advanced.³
Smoking is the leading cause of lung cancer but 20% of lung cancer diagnoses are non-smokers or never-smokers (two-thirds of those are women).⁴